Allogene Therapeutics, Inc. (ALLO)
NASDAQ: ALLO · Real-Time Price · USD
2.000
+0.040 (2.04%)
At close: May 22, 2026, 4:00 PM EDT
1.990
-0.010 (-0.50%)
After-hours: May 22, 2026, 7:49 PM EDT
Allogene Therapeutics Employees
As of December 31, 2025, Allogene Therapeutics had 152 total employees, including 150 full-time and 2 part-time employees. The number of employees decreased by 77 or -33.62% compared to the previous year.
Employees
152
Change (1Y)
-77
Growth (1Y)
-33.62%
Revenue / Employee
n/a
Profits / Employee
-$1,143,158
Market Cap
690.31M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 152 | -77 | -33.62% | 150 | 2 |
| Dec 31, 2024 | 229 | -4 | -1.72% | 226 | 3 |
| Dec 31, 2023 | 233 | -128 | -35.46% | 232 | 1 |
| Dec 31, 2022 | 361 | 51 | 16.45% | 359 | 2 |
| Sep 30, 2022 | 356 | 55 | 18.27% | 356 | 0 |
| Jun 30, 2022 | 344 | 59 | 20.70% | 344 | 0 |
| Mar 31, 2022 | 334 | 58 | 21.01% | 334 | 0 |
| Dec 31, 2021 | 310 | 45 | 16.98% | 308 | 2 |
| Sep 30, 2021 | 301 | 37 | 14.02% | 301 | 0 |
| Jun 30, 2021 | 285 | 49 | 20.76% | 285 | 0 |
| Mar 31, 2021 | 276 | 61 | 28.37% | 276 | 0 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Sep 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
Related Stocks
| Company Name | Employees |
|---|---|
| CorMedix | 191 |
| Solid Biosciences | 121 |
| BridgeBio Oncology Therapeutics | 92 |
| Aclaris Therapeutics | 73 |
| Alto Neuroscience | 68 |
| Zevra Therapeutics | 61 |
| Design Therapeutics | 54 |
| Crescent Biopharma | 44 |
ALLO News
- 2 days ago - Allogene Therapeutics Proxy statement: Proxy filing - Filings
- 7 days ago - Allogene Therapeutics Slides: Corporate presentation - Filings
- 9 days ago - Allogene Therapeutics Q1 Earnings Call Highlights - MarketBeat
- 9 days ago - Allogene Therapeutics ends China cell therapy deal with Overland - Reuters
- 9 days ago - Allogene Therapeutics reports Q1 EPS (18c), consensus (18c) - TheFly
- 9 days ago - Allogene Therapeutics increases 2026 operating cash expense guidance - TheFly
- 10 days ago - Allogene Therapeutics Earnings Call Transcript: Q1 2026 - Transcripts
- 10 days ago - Allogene Therapeutics Earnings release: Q1 2026 - Filings